Clinical Trials Browser

Laryngeal Neoplasms × Celecoxib × Clear all

NCT06997068 2026-05-11

Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population

Carcinoma, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT04162873 2025-02-12

Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer

Phase 2 Terminated

13 enrolled 36 charts

Head & Neck

Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Paranasal Sinus Neoplasms

NCT00052611 2018-03-29

Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia

Phase 2 Completed

23 enrolled

Head & Neck

Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Nasopharyngeal Neoplasms, Oropharyngeal Neoplasms, Salivary Gland Neoplasms

NCT00970502 2017-04-10

Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer

Phase 1/2 Completed

15 enrolled 16 charts

Head & Neck

Head and Neck Neoplasms, Laryngeal Neoplasms, Paranasal Sinus Neoplasms, Pharyngeal Neoplasms